News for Rezolute, Inc. (RZLT)

REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. ( RZLT) (”œRezolute” or the ”œCompany”), a late-stage rare disease company focuse

Rezolute (RZLT) to participate in BTIG Virtual Biotechnology Conference on July 29-30, 2025. Management to hold one-on-one meetings with investors during th

Rezolute, Inc. (RZLT) has initiated a process to sell 1.3 million shares of its common stock. This move is aimed at providing existing shareholders with an oppo

Rezolute (RZLT) will present Phase 3 sunRIZE study baseline data at ENDO 2025 on July 14, 2025. Topline data expected in December 2025, advancing potent

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Rezolute, Inc. (NASDAQ:RZLT) was one of the stocks that was covered in that article. Wall Street analysts believe RZLT has a 260% upside potential over the next 12 months. Rezolute, Inc. (NASDAQ:RZLT) is a late-stage biopharmaceutical company focused on addressing rare […]

sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Adminis

Rezolute (RZLT) has achieved a significant milestone with the U.S. Food and Drug Administration granting Breakthrough Therapy Designation to its experimental tr

**media[614538]**

REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. ( RZLT) (”œRezolute” or the ”œCompany”), a late-stage rare disease company focused

Rezolute has done well to continue to advance its lead drug from its pipeline, ersodetug. Click here to see why RZLT stock is a Buy.

H.C. Wainwright expressed no surprise at the decision by the independent data monitoring committee to maintain the current course of Rezolute's (RZLT) sunRIZE t

Rezolute, Inc. (RZLT) successfully closed its underwritten offering, raising approximately $96.9 million in net proceeds. The offering included 24,940,7

**media[606007]**

Biopharmaceutical company Rezolute, Inc. (RZLT) has announced the pricing of an underwritten public offering, aligning with Nasdaq regulations. This includes 20

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. ( RZLT) (”œRezolute” or the ”œCompany”), a late-stage biopharmaceutical company committed to

Rezolute, Inc. (RZLT) is moving forward with its Phase 3 sunRIZE clinical trial as planned, following positive feedback from the Data Monitoring Committee (DMC)

California-based Ensysce Biosciences, Inc. (ENSC) is up over 133 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

California-based Ensysce Biosciences, Inc. (ENSC) is up over 133 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Rezolute, Inc. (RZLT) prices $90 million offering, targeting significant capital infusion. Major participation from prominent investors like Blackstone